Restricted drug programs and REMS

What Are Risk Evaluation and Mitigation Strategies (REMS)?

The Food and Drug Administration (FDA) can require a drug manufacturer to implement a Risk Evaluation and Mitigation Strategy (REMS) when a medication's benefits are considered to outweigh its risks only if specific safety measures are in place. REMS programs exist because some drugs carry serious or life-threatening dangers — such as severe birth defects, dangerous blood disorders, or addiction — that standard labeling alone cannot adequately address.

A REMS may include one or more of the following elements:

• Medication Guides — FDA-approved written information given to patients each time a high-risk medication is dispensed.
• Communication plans — letters or education materials sent to healthcare providers.
• Elements to Assure Safe Use (ETASU) — the strictest tier, which may require prescriber certification, pharmacy certification, patient enrollment in a registry, laboratory testing before or during therapy, and limited dispense quantities.

As a pharmacy technician, your role is to help ensure REMS requirements are met before a prescription is filled or dispensed. You must never dispense a REMS-controlled medication without confirming that all required steps have been completed. Patient safety depends on this check.

iPLEDGE: Isotretinoin

iPLEDGE is the REMS program for isotretinoin (brand names include Absorica, Claravis, and others), an oral retinoid used for severe acne. Isotretinoin causes severe fetal abnormalities if taken during pregnancy — this is its most critical risk.

Under iPLEDGE:

• Prescribers must register and be certified in the program.
• Pharmacies must register and agree to dispense only to patients enrolled in the program.
• Patients must register, receive counseling, and — depending on their reproductive status — may need to confirm use of two forms of contraception and have a negative pregnancy test before each prescription is authorized.
• Prescriptions are authorized through the iPLEDGE online system. The pharmacy technician verifies that authorization exists in the system before the pharmacist can verify and dispense.
• Isotretinoin may only be dispensed in a 30-day supply, and no early refills are permitted.

As a technician, you should check the iPLEDGE system for a valid authorization number on every isotretinoin prescription and alert the pharmacist immediately if authorization is missing.

Clozapine REMS

Clozapine is an antipsychotic used for treatment-resistant schizophrenia and for reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Its most dangerous risk is severe neutropenia (dangerously low white blood cell count), which can be fatal.

The Clozapine REMS requires:

• Prescribers to be certified and to order and review absolute neutrophil count (ANC) laboratory tests on a scheduled basis.
• Patients to be enrolled and have current ANC results on file that meet minimum safe thresholds before a prescription can be dispensed.
• Pharmacies to be certified and to verify, through the REMS database, that the patient's current ANC qualifies for dispensing before each fill.

Dispensing is blocked at the pharmacy level if the ANC is below the required threshold or if lab results are not current. As a technician, you play a direct role in checking REMS system authorization and ensuring nothing leaves the pharmacy without that clearance.

Medication Guides

The FDA requires Medication Guides for drugs with serious risks that patients need to understand. These are specific, FDA-approved documents — not standard package inserts. A Medication Guide must be dispensed with each fill of the applicable medication, including refills. Examples include Medication Guides for antidepressants, blood thinners, and many REMS drugs.

The technician's responsibility includes making sure a current Medication Guide is printed and attached to the prescription bag. Failure to provide a Medication Guide when required is a compliance violation.

The Combat Methamphetamine Epidemic Act (CMEA)

The Combat Methamphetamine Epidemic Act of 2005, part of the USA PATRIOT Act reauthorization, established federal restrictions on retail sales of pseudoephedrine, ephedrine, and phenylpropanolamine — ingredients that can be used to manufacture methamphetamine.

Key requirements for pharmacies under CMEA include:

• Products containing these ingredients must be kept behind the counter or in a locked cabinet — not on open shelves.
• Purchasers must show a government-issued photo ID and provide their name and address.
• The pharmacy must maintain a written or electronic logbook of each sale, including the purchaser's name and address, date and time of sale, and product and quantity sold. Purchasers sign the logbook.
• Daily purchase limit: no more than 3.6 grams of pseudoephedrine base per day to any single purchaser.
• 30-day purchase limit: no more than 9 grams of pseudoephedrine base per 30-day period.
• Sellers must be trained on CMEA requirements.

Some states have enacted stricter limits or require a prescription for pseudoephedrine products. Always follow the more restrictive rule — state or federal — whichever is stricter.

Your Role and Patient Safety

Restricted drug programs exist because the consequences of skipping a required safety step can be irreversible — a pregnancy exposed to isotretinoin, a patient with undetected neutropenia given clozapine, or pseudoephedrine diverted to illegal drug manufacturing. As a technician, you are a critical checkpoint. If any REMS requirement has not been met, stop, do not dispense, and consult the pharmacist immediately.